ReviewTargeted oncology2011
Pulmonary toxicities from targeted therapies: a review.
Review in Targeted oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Pooled it
- Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature.Journal of clinical medicine · 2026Review
- An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System.The clinical respiratory journal · 2025Article
- Pulmonary Manifestations in Patients With Hematologic Malignancies: In Pursuit of an Accurate Diagnosis.Cureus · 2025Review
- Therapeutic impacts of GNE‑477‑loaded HInternational journal of molecular medicine · 2024Article
- Cytoplasmic retention of the DNA/RNA-binding protein FUS ameliorates organ fibrosis in mice.The Journal of clinical investigation · 2024Article
- Hemoptysis in Cancer Patients.Cancers · 2023Review
- Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience.The Korean journal of internal medicine · 2021Article
- Review
- Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases.Journal of thoracic disease · 2020Review
- Repurposing of Kinase Inhibitors for Treatment of COVID-19.Pharmaceutical research · 2020Review
- Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing?Pharmacogenomics · 2020Article
- [Pulmonary involvement in cancers].Der Pneumologe · 2020Article
- Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2020Article
- Panitumumab-induced pulmonary toxicity.Current oncology (Toronto, Ont.) · 2019Article
- Incidence of Bleeding Complications With Flexible Bronchoscopy in Cancer Patients With Thrombocytopenia.Journal of bronchology & interventional pulmonology · 2019Article
- A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.BMJ case reports · 2019Article
- Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.BMC pharmacology & toxicology · 2018Article
- Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2018Review
- Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary toxicity is rarely seen with most commonly used targeted therapies. The endothelial growth factor receptor (EGFR) small-molecule tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib can cause interstitial lung disease (ILD). BCR-ABL tyrosine kinase inhibitors imatinib and dasatinib can cause pleural effusions. Infusion-related bronchospasm is common with the monoclonal antibodies to EGFR cetuximab and panitumumab, and case reports of bronchiolitis and pulmonary fibrosis have been described. Up to one-sixth of patients taking mammalian target of rapamycin (mTOR) inhibitors get a reversible interstitial pneumonitis. Bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF), has been associated with hemoptysis and pulmonary embolism particularly in patients with squamous cell lung cancer. Infusion-related bronchospasms, acute respiratory distress syndrome (ARDS), and interstitial pneumonitis can be seen with the anti-lymphocyte monoclonal antibodies rituximab, ofatumumab, and alemtuzumab. While most pulmonary toxicities from these therapies are mild and resolve promptly with dose reduction or discontinuation, it is important for the clinician to recognize these potential toxicities when faced with treatment-related complications. Discerning these pulmonary adverse effects may help in making decisions on diagnostic testing and therapy, particularly for those with pulmonary and cardiovascular co-morbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.